Skip to main content

Pharma News

Pharma Courses

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • Phase 3 trial recruitment starts for COVID-19 vaccine of Janssen

    The University of Kentucky has been selected as a testing site for the Janssen Pharmaceutical Companies of Johnson & Johnson’s Phase 3 clinical research study ENSEMBLE 2, which is evaluating the safety and efficacy of a two-dose regimen of Janssen’s COVID-19 vaccine candidate.

  • Takeda submits NDA for a drug uitlised in Perianal Fistulas in Crohn’s disease at Japan

    Takeda Pharmaceutical Company Limited announced that it has submitted an application to the Japanese Ministry of Health, Labour and Welfare to manufacture and market darvadstrocel (development code: Cx601) for the treatment of complex perianal fistulas in adult patients with non-active/mildly active luminal Crohn’s disease (CD).

  • Umbralisib has received US FDA accelerated approval for relapsed or refractory lymphomas

    Rhizen Pharmaceuticals, a clinical-stage oncology-focused biopharmaceutical company, announced that its novel next generation PI3K-delta inhibitor, Umbralisib, which was licensed to TG Therapeutics has secured USFDA accelerated approval for the treatment of : (1) adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20 based regimen, and (2) adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least three prior lines of systemic therapy.

  • International Harmonising of the standards and specifications will boost the Medical devices Industry in India

    Health and Pharmaceutical Manufacturing & Medical Devices Committee, PHDCCI in association with Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers, Govt. of India organized third series of Self Sufficiency in Medical Technology on “India to be an attractive destination for MedTech” on 5th February 2021

  • USFDA Approves Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel)

    Bristol Myers Squibb announced that the U.S.

  • India is also providing vaccines to neighboring countries

    In this difficult time when the whole world has suffered from an unknown, invisible and unknowable virus COVID-19, India is ready to provide its cut to the world community. India, which has become the Corona vaccine, is running the world's largest vaccination campaign today. Not only this, along with the vaccination of Corona to Indians, India is also providing vaccines to many other countries.

  • 21% of India’s adult population had COVID-19 by mid-December : Serological Survey

    According to the third national serological-survey report of the Indian Council of Medical Research (ICMR), over 21 percent of the population, aged 18 years and above, showed evidence of past exposure to COVID-19. The data on seroprevalenceamong those aged 10-17 was found to be 25.3 percent.

  • Pfizer withdraws application for COVID-19 vaccine from India

    Pfizer has decided to withdraw the application for Emergency Use Authorisation (EUA) of its COVID-19 vaccine in India. Pfizer was amongst the other industries like Dr. Reddy's Lab and Zydus Cadila which was seeking DCGI approval for their COVID-19 vaccine for EUA.

    Pfizer India was the first company to apply for EUA in India on 4th December 2020 for it's mRNA Covid-19 vaccine just after it had received an emergency approval in the United Kingdom.

  • Merck and BioNTech Extend Strategic Partnership Through Accelerated Supply of Urgently Needed Lipids

    Merck and BioNTech are further expanding their strategic partnership. Merck, in close collaboration with BioNTech, will significantly accelerate the supply of urgently needed lipids and increase the amount of lipid delivery towards the end of 2021. The lipids will be used for the production of the Pfizer-BioNTech Covid-19 Vaccine (BNT162b2).

  • NTHU Researchers Take Robotics to the Next Level

    Although widely used in manufacturing, robots require much more agility for use in nursing and rehabilitation. With this in mind, an interdisciplinary research team led by Professor James Chang of the Department of Power Mechanical Engineering has recently applied the latest advances in AI, biomechanics, and human-factor engineering to develop a robot that can imitate the meticulous movements of a human hand. Endowed with sharp senses of vision and touch, the robot’s hands are nimble enough to catch a ball and pull out a tissue.

Subscribe to Pharma News